Lupron, Lupron Depot, Eligard, Fensolvi
Evidence Grade A — Regulatory approved. 2314 published studies. 102 registered clinical trials.
Loading...
Leuprolide (sold as Lupron Depot, Eligard, and Fensolvi) is one of the most widely used hormone-suppressing medications in the world. Given as a depot injection lasting one to six months, it dramatically reduces testosterone or oestrogen levels and is prescribed across multiple medical specialities — for prostate cancer, endometriosis, uterine fibroids, central precocious puberty in children, and as part of fertility treatment.
2,314 published studies: 1705 human, 278 animal, 342 in-vitro, 200 reviews
Leuprolide is marketed as Lupron Depot, Eligard, and Fensolvi, and was first approved in 1985. It is available in depot formulations lasting one, three, four, or six months. Its clinical applications span multiple specialities: oncology (advanced prostate cancer), gynaecology (endometriosis, uterine fibroids), paediatric endocrinology (central precocious puberty), and reproductive medicine.
Leuprolide's long clinical history provides extensive safety data. The initial hormone surge in the first one to two weeks can temporarily worsen symptoms — a well-known effect called 'flare' that is managed by co-prescribing an anti-androgen in prostate cancer patients. Long-term use carries risks including bone density loss, cardiovascular effects, and metabolic changes. Despite the availability of newer GnRH antagonists that avoid the initial flare, leuprolide remains the dominant treatment in this category due to its proven track record and range of formulations.
Your brain's pituitary gland releases sex hormones in a pulsed pattern. Leuprolide mimics the natural signalling hormone (GnRH) that controls this process, but instead of pulsing, it provides a constant signal. After an initial brief surge in hormone levels lasting one to two weeks, this continuous stimulation causes the pituitary gland to shut down its hormone production entirely. The result is a dramatic and sustained drop in testosterone or oestrogen levels. This is used therapeutically in conditions that are driven or worsened by sex hormones, such as prostate cancer (testosterone-dependent) and endometriosis (oestrogen-dependent).
Leuprolide has been in clinical use since 1985 with four decades of safety data. Its long track record and wide range of depot formulations (one-month, three-month, four-month, and six-month options) make it the dominant GnRH agonist despite the availability of newer alternatives. The well-known limitation is the initial hormone flare in the first one to two weeks — testosterone or oestrogen levels rise temporarily before the suppressive effect takes hold. In prostate cancer, this flare can worsen symptoms like bone pain, requiring co-administration of an anti-androgen. GnRH antagonists (degarelix, relugolix) avoid this flare entirely, and oral relugolix in particular has emerged as a convenient alternative. Long-term hormone suppression carries risks including bone density loss, hot flashes, cardiovascular effects, and metabolic changes. Generic versions exist, though the complexity of depot formulation technology limits straightforward substitution.
The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
FDA ORIG 1
FDA SUPPL 2
FDA SUPPL 3
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 3
FDA SUPPL 7
FDA SUPPL 6
FDA SUPPL 4
FDA SUPPL 8
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 11
FDA SUPPL 7
FDA SUPPL 10
FDA SUPPL 6
FDA SUPPL 9
FDA SUPPL 9
FDA SUPPL 10
FDA SUPPL 13
FDA SUPPL 12
FDA SUPPL 11
FDA SUPPL 14
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 12
FDA SUPPL 16
FDA SUPPL 15
FDA SUPPL 13
FDA SUPPL 17
FDA SUPPL 14
FDA SUPPL 18
FDA SUPPL 19
FDA SUPPL 15
FDA SUPPL 20
FDA SUPPL 2
FDA SUPPL 17
FDA ORIG 1
FDA SUPPL 21
FDA SUPPL 18
FDA SUPPL 1
FDA SUPPL 19
FDA SUPPL 22
FDA SUPPL 24
FDA SUPPL 20
FDA SUPPL 2
FDA SUPPL 23
FDA SUPPL 22
Health Canada Market Authorisation
FDA SUPPL 23
FDA SUPPL 26
FDA SUPPL 4
FDA SUPPL 24
FDA SUPPL 29
FDA SUPPL 27
FDA SUPPL 26
FDA SUPPL 28
FDA SUPPL 6
FDA SUPPL 15
FDA SUPPL 7
FDA SUPPL 30
FDA ORIG 1
FDA SUPPL 33
FDA SUPPL 36
FDA SUPPL 35
FDA SUPPL 31
FDA SUPPL 35
FDA SUPPL 18
FDA SUPPL 37
FDA SUPPL 19
FDA SUPPL 10
FDA SUPPL 3
FDA SUPPL 20
FDA SUPPL 5
FDA SUPPL 36
FDA SUPPL 11
FDA SUPPL 37
FDA SUPPL 38
FDA SUPPL 27
FDA SUPPL 26
FDA SUPPL 39
FDA SUPPL 40
FDA SUPPL 29
FDA SUPPL 41
FDA SUPPL 28
FDA SUPPL 30
FDA SUPPL 31
FDA SUPPL 12
FDA SUPPL 32
FDA SUPPL 14
FDA SUPPL 33
FDA SUPPL 42
FDA SUPPL 34
FDA SUPPL 17
FDA SUPPL 18
FDA SUPPL 14
FDA SUPPL 15
FDA SUPPL 42
FDA ORIG 1
FDA SUPPL 43
FDA SUPPL 39
FDA SUPPL 44
FDA SUPPL 46
FDA ORIG 1
FDA SUPPL 22
FDA SUPPL 20
FDA SUPPL 44
FDA SUPPL 47
FDA ORIG 1
FDA SUPPL 48
FDA SUPPL 45
FDA SUPPL 2
FDA SUPPL 50
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 3
FDA SUPPL 4
FDA SUPPL 53
FDA SUPPL 47
FDA SUPPL 48
FDA SUPPL 5
FDA SUPPL 54
FDA SUPPL 48
FDA SUPPL 51
FDA SUPPL 4
FDA SUPPL 49
FDA SUPPL 52
FDA SUPPL 6
FDA SUPPL 4
FDA ORIG 1
FDA SUPPL 7
FDA SUPPL 55
FDA SUPPL 6
FDA SUPPL 56
FDA SUPPL 7
FDA SUPPL 56
FDA SUPPL 50
FDA SUPPL 32
FDA SUPPL 11
FDA SUPPL 34
FDA SUPPL 39
FDA SUPPL 58
FDA SUPPL 9
FDA SUPPL 10
FDA SUPPL 2
FDA SUPPL 57
FDA SUPPL 11
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
